Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1Abiraterone Acetate 1

Interventions

pembrolizumab 2enfortumab vedotin 2sagopilone 1glutamic acid diethyl ester 1allantoicase 1Single Person 1Prednisolone 1Glutamine 1Glutamic Acid 1Exercise 1Dietary Supplements 1BID protein, human 1Acupuncture Therapy 1Acetylcarnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × BID protein, human × Genitourinary × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡